Valence ロゴ
人気
ログイン
Loading data for DERM — first visit, this takes a few seconds.

ウォッチリストに追加

Journey Medical Corporati...

NasdaqCM: DERM · リアルタイム株価 · USD
6.46
-0.26 (-3.87%)
終値時点： Aug 19, 2026, 3:59 PM
6.89
+1.19%
時間外: 6:11 PM

Journey Medical Corporation (DERM) Stock Price, Analysis & Data

-3.87%
買気配4.76
時価総額192.21M
売上高（TTM）68.18M
純利益（TTM）-6.1M
ベータ1.08
EPS（TTM）-0.22
PER（TTM）n/a
予想PER-113.5
PBR（TTM）5.81
PSR（TTM）2.82
Earnings DateNov 11, 2026
売気配8.35
出来高287,622
平均出来高（20日）256,918
始値6.73
前日終値6.72
当日レンジ6.45 - 6.81
52週レンジ4.31 - 9.55
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

DERMについて

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topica...

[続きを読む]
業種 Drug Manufacturers - Specialty & Generic
セクター Healthcare
IPO日 Nov 12, 2021
従業員数 58
上場取引所 NasdaqCM
ティッカー DERM
ウェブサイト https://journeymedicalcorp.com
企業情報の全文

業績

2025年のJourney Medicalの売上高は61.86Mで、前年の56.13Mから10.2%の増加でした。 利益は-11.43Mで、-22.09%の減少でした。

財務諸表

決算サプライズ

Journey MedicalはAug 12, 2026に四半期決算を発表しました：
  • 売上高は $15.96M で、予想を下回りました $0, うち 21.48% の前年比増加にあたります.
  • EPSは -0.01 で、予想を上回りました 0.01, うち 93.75% の前年比増加にあたります.

    • 次回決算発表

    Journey Medical Corporationの決算発表予定日は Nov 11, 2026, 取引時間中の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    6日前 · GuruFocus.com

    Journey Medical Corp (DERM) (Q2 2026) Earnings Call Highlights: Emrosi Surges 20% Sequentially, ...

    Journey Medical Corp (DERM) narrows net loss to $300K as Emrosi prescriptions hit all-time highs and payer access expands.

    news image

    6日前 · Moby

    Journey Medical Corporation Q2 2026 Earnings Call Summary

    Moby summary of Journey Medical Corporation's Q2 2026 earnings call

    news image

    6日前 · MarketBeat

    Fortress Biotech Q2 Earnings Call Highlights

    Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Exe...

    news image

    6日前 · MarketBeat

    Journey Medical Q2 Earnings Call Highlights

    Journey Medical (NASDAQ:DERM) reported higher second-quarter revenue and a sharply narrower net loss as sales of its rosacea treatment EMROSI continued to grow, supported by rising prescription volume...

    news image

    6日前 · Zacks

    Here's What Key Metrics Tell Us About Journey Medical (DERM) Q2 Earnings

    The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street e...

    2ページ中1ページ